New brain scan tracks Dementia-Linked tau buildup in rare language disorders
NCT ID NCT02736695
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a special PET scan tracer (F-18 AV 1451) to see how much tau protein builds up in the brains of 81 people with primary progressive aphasia or frontotemporal dementia. Researchers compared these scans to those of healthy controls to find unique patterns for each disease subtype. The goal was to improve understanding and diagnosis, not to test a treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
F-18 AV 1451 (a radioactive tracer for PET scans)
What this could lead to
If successful, this could help doctors better diagnose and distinguish different types of frontotemporal dementia and primary progressive aphasia using brain scans.
What could go wrong
This is an early-phase, observational study focused on imaging, not a treatment trial. The tracer may not reliably distinguish all subtypes, and results may not directly improve patient care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRONTOTEMPORAL DEMENTIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States